Maryland Capital Management Lowers stake in United Therapeutics Corporation (UTHR)

United Therapeutics Corporation (UTHR) : Maryland Capital Management reduced its stake in United Therapeutics Corporation by 14.17% during the most recent quarter end. The investment management company now holds a total of 160,044 shares of United Therapeutics Corporation which is valued at $20,035,908 after selling 26,413 shares in United Therapeutics Corporation , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.United Therapeutics Corporation makes up approximately 2.99% of Maryland Capital Management’s portfolio.

Other Hedge Funds, Including , South Dakota Investment Council boosted its stake in UTHR in the latest quarter, The investment management firm added 13,000 additional shares and now holds a total of 61,700 shares of United Therapeutics Corporation which is valued at $7,724,223. United Therapeutics Corporation makes up approx 0.16% of South Dakota Investment Council’s portfolio.Fca Corp Tx boosted its stake in UTHR in the latest quarter, The investment management firm added 750 additional shares and now holds a total of 2,750 shares of United Therapeutics Corporation which is valued at $344,493. United Therapeutics Corporation makes up approx 0.17% of Fca Corp Tx’s portfolio.Dupont Capital Management Corp reduced its stake in UTHR by selling 1,540 shares or 5.95% in the most recent quarter. The Hedge Fund company now holds 24,360 shares of UTHR which is valued at $3,041,590. United Therapeutics Corporation makes up approx 0.07% of Dupont Capital Management Corp’s portfolio.Ibm Retirement Fund reduced its stake in UTHR by selling 189 shares or 4.07% in the most recent quarter. The Hedge Fund company now holds 4,451 shares of UTHR which is valued at $495,886. United Therapeutics Corporation makes up approx 0.02% of Ibm Retirement Fund’s portfolio.Cibc World Markets boosted its stake in UTHR in the latest quarter, The investment management firm added 68 additional shares and now holds a total of 6,322 shares of United Therapeutics Corporation which is valued at $704,334.

United Therapeutics Corporation opened for trading at $124.91 and hit $127.15 on the upside on Friday, eventually ending the session at $126.92, with a gain of 1.03% or 1.3 points. The heightened volatility saw the trading volume jump to 4,08,248 shares. Company has a market cap of $5,517 M.

On the company’s financial health, United Therapeutics Corporation reported $4.55 EPS for the quarter, beating the analyst consensus estimate by $ 1.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $3.52. The company had revenue of $412.60 million for the quarter, compared to analysts expectations of $395.00 million. The company’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.55 EPS.

Many Wall Street Analysts have commented on United Therapeutics Corporation. Shares were Downgraded by H.C. Wainwright on Jun 15, 2016 to ” Neutral” and Lowered the Price Target to $ 95 from a previous price target of $175 .

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company’s key therapeutic products and product candidates include Remodulin Tyvaso (treprostinil) Adcirca (tadalafil) Remodulin Implantable System Orenitram Combination Therapy Esuberaprost and PLX Cells for the treatment of Pulmonary Arterial Hypertension; Ch14.18 MAb for the treatment of High-risk neuroblastoma; Ex-Vivo Lung Perfusion and Lung Transplantation for the treatment of End-stage lung disease; UV-4B for the treatment of Dengue and influenza and Glycobiology Antiviral Agents for the treatment of a spectrum of agents against viral infectious diseases among others. The Company’s lead product for treating Pulmonary Arterial Hypertension (PAH) is Remodulin.

Leave a Reply

United Therapeutics Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on United Therapeutics Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.